Compare WFCF & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WFCF | EQ |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.1M | 57.8M |
| IPO Year | 2011 | 2018 |
| Metric | WFCF | EQ |
|---|---|---|
| Price | $12.83 | $1.09 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 3.8K | ★ 458.0K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.82 | N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $25,512,000.00 | $4,392,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.90 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.26 | $0.27 |
| 52 Week High | $13.78 | $2.35 |
| Indicator | WFCF | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 63.28 | 53.63 |
| Support Level | $12.50 | $0.84 |
| Resistance Level | $13.15 | $0.92 |
| Average True Range (ATR) | 0.41 | 0.11 |
| MACD | 0.15 | 0.02 |
| Stochastic Oscillator | 100.00 | 70.11 |
Where Food Comes From Inc is a third-party food verification company. It offers food production audits and uses verification processes to ensure that claims made by food producers and processors are accurate. The company supports farmers, ranchers, vineyards, wineries, processors, retailers, distributors, trade associations, and restaurants with a wide variety of value-added services provided through its family of verifiers, including International Certification Services, Validus Verification Services, and others. The company operates in two segments that are verification and certification and Software Sales and Related Consulting. It generates the majority of its revenue from verification and certification.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.